About Bienta

Bienta is a trademark for preclinical biology services of Enamine, the world’s largest supplier of drug-like molecules for drug discovery research. Bienta is operating as a Contract Research Organisation (CRO) providing biomolecular screening (HTS) services as well as comprehensive bioanalytical support of drug discovery projects, including in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) testing as well as pharmacokinetics (PK) and toxicity studies in animals.

Time- and Cost-Effective Screening

Rapid direct access to the vast Enamine’s off-the shelf compound collection (Screening Collection) and Enamine’s explored virtual chemical space for drug-like structures (REAL Database™),  in combination with the powerful in-house chemoinformatics and molecular modeling, enables an exceptionally efficient iterative screening, making it possible to step forward from in silico screening sets to the lead generation stage in weeks.

High Throughput Screening & ADME-Tox Services

HTS Lab at Bienta is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities as well as the capacity to run both biochemical and cell-based assays in 384-well plate format. Bioanalytical Lab is established to provide all common in vitro ADMET tests as well as analytical support of pharmacokinetics and animal tox services.

Discover your molecules with us

News & Events

In Vivo Facility Expansion

To address rapidly growing demand in in vivo pharmacokinetic and toxicology studies, Bienta is currently building a new animal research facility. The new in vivo research lab will occupy over 500 m2 of lab space, equipped and maintained under highest quality standards.  The new facility will be hosting up to 5000 animals (small rodents) and will allow to expand the list of animal testing services...

Enamine, EMBL Agree to Library Synthesis and Drug Discovery Services Collaboration

Enamine and the European Molecular Biology Laboratory (EMBL) agreed to a collaboration through which Enamine will provide library synthesis, medicinal chemistry, and biological services for EMBL’s small-molecule cancer drug discovery programs. Enamine will establish a team of full-time equivalent medicinal chemists to work on the project, which is focused on the development of cancer therapeutics with novel mechanisms of...

3rd Prague Summer School Advances in Drug Discovery

Sergey Zozulya, Bienta’s CTO, participated in 3rd Prague Summer School Advances in Drug Discovery, with the lecture “High-throughput screening of compound libraries”. The School took place in Prague, September 5-9th, 2016, and focused on Drug Discovery and Development, from basic research through preclinical to clinical...

Read More